-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542

Benzinga·06/11/2026 12:10:29
Listen to the news
B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral and lowers the price target from $550 to $542.